Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Anna F Farago, Long P Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, Manish Patel, Todd M Bauer, Stephen V Liu, Sai-Hong I Ou, David Jackman, Daniel B Costa, Pratik S Multani, Gary G Li, Zachary Hornby, Edna Chow-Maneval, David Luo, Jonathan E Lim, Anthony J Iafrate, Alice T Shaw, Anna F Farago, Long P Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, Manish Patel, Todd M Bauer, Stephen V Liu, Sai-Hong I Ou, David Jackman, Daniel B Costa, Pratik S Multani, Gary G Li, Zachary Hornby, Edna Chow-Maneval, David Luo, Jonathan E Lim, Anthony J Iafrate, Alice T Shaw

Abstract

Introduction: Chromosomal rearrangements involving neurotrophic tyrosine kinase 1 (NTRK1) occur in a subset of non-small cell lung cancers (NSCLCs) and other solid tumor malignancies, leading to expression of an oncogenic TrkA fusion protein. Entrectinib (RXDX-101) is an orally available tyrosine kinase inhibitor, including TrkA. We sought to determine the frequency of NTRK1 rearrangements in NSCLC and to assess the clinical activity of entrectinib.

Methods: We screened 1378 cases of NSCLC using anchored multiplex polymerase chain reaction (AMP). A patient with an NTRK1 gene rearrangement was enrolled onto a Phase 1 dose escalation study of entrectinib in adult patients with locally advanced or metastatic tumors (NCT02097810). We assessed safety and response to treatment.

Results: We identified NTRK1 gene rearrangements at a frequency of 0.1% in this cohort. A patient with stage IV lung adenocrcinoma with an SQSTM1-NTRK1 fusion transcript expression was treated with entrectinib. Entrectinib was well tolerated, with no grade 3-4 adverse events. Within three weeks of starting on treatment, the patient reported resolution of prior dyspnea and pain. Restaging CT scans demonstrated a RECIST partial response (PR) and complete resolution of all brain metastases. This patient has continued on treatment for over 6 months with an ongoing PR.

Conclusions: Entrectinib demonstrated significant anti-tumor activity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene rearrangement, indicating that entrectinib may be an effective therapy for tumors with NTRK gene rearrangements, including those with central nervous system metastases.

Conflict of interest statement

Disclosure: AFF has received consultant fees from Intervention Insights. LPL has received consultant fees from and has equity in ArcherDx. AD has received honoraria and travel expenses, and has served on the speaker’s Bureau for Ignyta, Inc. DJ has received consultant fees from Genentech and Celgene. DBC has received honoraria and consultant fees from Pfizer, honoraria from Boehringer Ingelheim, and consultant fees from Aria Pharmaceuticals. PSM, GGL, ZH, EC-M, DL and JL are employees of and have equity in Ignyta, Inc. AJI has received consultant fees and has equity in ArcherDx, and has received consulting fees from Chugai, Constellation, and DebioPharm. ATS has received consultant fees or served on the advisory board for Ignyta, Inc., Pfizer, Novartis, Genentech, Roche, Blueprint Medicine, and EMD Serono. ZZ, AM, MP, TMB, SVL, and S-HIO declare no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
SQSTM1-NTRK1 fusion transcripts detected by AMP in a NSCLC. (A) Contiguous reads from amplified transcripts mapped to the locations of SQSTM1 on chromosome 5 and NTRK1 on chromosome 1 (red arrowheads). (B) Visualization of subset of sequence read pileup showing fusion reads. The y axis represents read coverage. The x axis represents reference bases and their respective codons below. Shown in gray are read portions corresponding to the randomly ligated universal adapter end with staggered distribution of reads and differing start positions. Shown in blue are read portions corresponding to the anchored end targeted with GSP1 and GSP2. The fusion is in-frame with respect to both transcripts. (C) Schematic drawing of gene fusion involving SQSTM1 and NTRK1. TM, transmembrane domain. Not drawn to scale. (D) FISH confirmation SQSTM1-NTRK1 rearrangement showed individual 3’ (red only) probe signals that represent a region downstream of the NTRK1 gene along with normal paired green and red signals that represent non-rearranged alleles. White arrows highlight representative red only signals.
FIGURE 2.
FIGURE 2.
Partial response to entrectinib. Horizontal (A) and coronal (B) images of the chest at day -7 (baseline scan), day 26 (C, D), and day 155 (E, F) on entrectinib.
FIGURE 3.
FIGURE 3.
Complete response of brain metastases to entrectinib. (A-C) Baseline head CT scan at day -7 demonstrating metastases (green arrows) in the right thalamus (A), left occipital lobe (B) and left cerebellum (C). (D-I) Restaging head CT scans at day 26 (D-F) and day 155 (G-I) on entrectinib.
FIGURE 4.
FIGURE 4.
Trk signaling. (A) Schematic diagrams showing wild-type TrkA, TrkB or TrkC protein, top, and showing an oncogenic fusion involving a partner gene that contains a dimerization domain and the kinase domain of TrkA, TrkB or TrkC, bottom. Of note, the fusion shown here includes the transmembrane (TM) domain, though Trk fusion proteins that lack the TM domain have also been described. (B) In the absence of ligand, left, Trk proteins do not dimerize or activate downstream signaling pathways. In the presence of ligand (red circle), Trk proteins dimerize, leading to downstream pathway activation. Double line represents the cell membrane. (C) Fusion oncogenes dimerize in a ligand-independent manner, leading to constituative activation and downstream signaling. Proteins and their domains are not draw to scale.

References

    1. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13(11):772–787.
    1. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4(4):299–309.
    1. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–1472.
    1. Doebele RC, Davis LE, Vaishnavi A, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Jul 27;5(10):1049–1057.
    1. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.
    1. Anderson D, Ciomei M, Banfi P, et al. Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101; Paper presented at: 26th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Theapeutics2014; Barcelona, Spain:
    1. Lee SJ, Li GG, Kim ST, et al. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget. 2015
    1. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479–1484.
    1. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007 Aug 17;282(33):24131–24145.
    1. Iyevleva AG, Raskin GA, Tiurin VI, et al. Novel ALK fusion partners in lung cancer. Cancer Lett. 2015;362(1):116–121.
    1. Takeuchi K, Soda M, Togashi Y, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica. 2011;96(3):464–467.
    1. Tatematsu T, Sasaki H, Shimizu S, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451. Mol Clin Oncol. 2014;2(5):725–730.
    1. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren